TACC Names Hospitals Taking Part in Patient Navigator Program
The American College of Cardiology (ACC) is launching a program that applies a team approach to keeping patients at home and healthy after discharge from the hospital. The ACC Patient Navigator Program was started in response to the increased penalties in effect beginning October 1, 2013, for hospitals with excessive readmission rates within 30 days of discharge for heart attack and heart failure.
The program supports a team of caregivers at selected hospitals to help patients overcome challenges during their hospital stay and in the weeks following discharge, when they are most a risk for readmission.
The ACC Patient Navigator Program will serve as a test for innovative patient-centered solutions to address issues that affect patient health and readmissions, said ACC President John G. Harold, MD, MACC. “These hospitals will serve as pioneers in a new approach to heart disease treatment and care that puts emphasis on meeting patients’ ongoing needs and helping patients make a seamless transition from the hospital to the home.”
Nearly 1 in 5 patients hospitalized with heart attack and 1 in 4 hospitalized with heart failure are readmitted within 30 days of discharge, often for conditions that seem to be unrelated to the original diagnosis, according to the ACC.
The first 11 hospitals participating in the ACC Patient Navigator Program, chosen because of their commitment to quality demonstrated by participation in the National Cardiovascular Data Registry and Hospital to Home program, include:
AstraZeneca is the founding sponsor of the ACC Patient Navigator Program.
Guidance on Transcatheter Txs for Mitral Regurgitation
Anew overview issued by the American College of Cardiology (ACC), the American Association for Thoracic Surgery (AATS), the Society of Thoracic Surgeons (STS), and the Society for Cardiovascular Angiography and Interventions (SCAI) Foundation states that it is imperative that professional societies, industry, taxpayers, and regulatory agencies collaborate to promote needed research and ensure appropriate integration of transcatheter therapies for the treatment of patients with severe mitral regurgitation (MR).
The societies say that a number of transcatheter therapies for MR are expected to be available for clinical use in the coming years. Therefore, a thoughtful process is needed to ensure that such innovative treatments are introduced into medical practice in the United States with appropriate safeguards.
The overview contains several recommendations for appropriate integration, including the following:
Visit www.cardiosource.org/en/News-Media/Publications/Cardiology-Magazine/2013/11/New-Societal-Overview-Aims-to-Provide-Guidance-on-Transcatheter-Therapies-for-Mitral-Regurgitation.aspx?print=1 for more information.
Wider Use of Statins Recommended for CKD
Aworking group of the Kidney Disease: Improving Global Outcomes (KDIGO) recommends wider statin use among patients with chronic kidney disease (CKD) and published a synopsis of the key recommendations on lipid management and monitoring in adults with CKD in the December 9, 2013, issue of the Annals of Internal Medicine.
Specific LDL cholesterol treatment targets were removed from the guidelines on managing lipids in patients with CKD, instead basing the decision to start cholesterol-lowering treatment on the absolute risk of coronary events, and evidence that a therapy will help lower that risk.
Marcello Tonelli, MD, of the University of Alberta, Canada, and colleagues present a synopsis of 8 key recommendations in KDIGO’s 2013 practice guidelines.
The key recommendations for statin treatment in patients with CKD include:
Some experts are critical of the new recommendations, however, pointing out that except for a single 1A recommendation, they are mostly graded 2B and 2C, and number needed to treat and number needed to harm are not provided.